Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.


  • Gene variants involved in stress responses affect 'post-concussive' symptoms

  • Reduced blood flow seen in brain after clinical recovery of acute concussion

  • Imaging identifies cartilage regeneration in long-distance runners

  • Newly evolved, uniquely human gene variants protect older adults from cognitive decline

  • DNA repair protein BRCA1 implicated in cognitive function and dementia

  • Synapse discovery could lead to new treatments for Alzheimer's disease

  • Structural brain connectivity as a genetic marker for schizophrenia

  • And when the bubbles burst, thunder in neurons

  • Molecular trigger for cerebral cavernous malformation identified

  • Even the elderly can recover from a severe traumatic brain injury